See every side of every news story
Get Started
SubscribeLogin
Everton
Donald Trump
Ukraine War
Volodymyr Zelenskyy
Viktor Orbán
Hamas
Basketball
Israel-Hamas Conflict
Manchester United
Elon Musk
Premier League
Soccer
Published • loading... • Updated

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million - AstraZeneca (NASDAQ:AZN), FibroGen (NASDAQ:FGEN)

Summary by Benzinga
FibroGen Inc. (NASDAQ:FGEN) stock is trading higher on Thursday. The company announced the sale of its China subsidiary to AstraZeneca Plc (NASDAQ:AZN) for approximately $160 million. “Today, we announced the sale of FibroGen China to AstraZeneca, our long-time strategic partner for roxadustat in China, bolstering our company on several fronts. It strengthens our financial position, meaningfully extending our cash runway into 2027, and enables u…

6 Articles

All
Left
Center
1
Right
BenzingaBenzinga

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million - AstraZeneca (NASDAQ:AZN), FibroGen (NASDAQ:FGEN)

FibroGen Inc. (NASDAQ:FGEN) stock is trading higher on Thursday. The company announced the sale of its China subsidiary to AstraZeneca Plc (NASDAQ:AZN) for approximately $160 million. “Today, we announced the sale of FibroGen China to AstraZeneca, our long-time strategic partner for roxadustat in China, bolstering our company on several fronts. It strengthens our financial position, meaningfully extending our cash runway into 2027, and enables u…

·New York, United States
Read Full Article
DealbreakerDealbreaker

AstraZeneca Secures China Rights to Anemia Drug, Buying FibroGen Unit in $160M Deal

An anemia drug developed under an alliance between FibroGen and AstraZeneca will continue its commercialization in China fully in the hands of the pharmaceutical giant, which is buying the China business of its partner in a $160 million deal.The agreement announced Thursday covers the rights to roxadustat in China, where the drug has become a top-selling product for treating anemia caused by chronic kidney disease. San Francisco-based FibroGen w…

Read Full Article
English TimesEnglish Times

AstraZeneca Secures China Rights to Anemia Drug, Buying FibroGen Unit in $160M Deal – English Times

An anemia drug developed under an alliance between FibroGen and AstraZeneca will continue its commercialization in China fully in the hands of the pharmaceutical giant, which is buying the China business of its partner in a $160 million deal. The agreement announced Thursday covers the rights to roxadustat in China, where the drug has become a top-selling product for treating anemia caused by chronic kidney disease. San Francisco-based FibroGen …

Read Full Article
pharmaceutical-technology.compharmaceutical-technology.com

FibroGen sells China unit to AstraZeneca for $160m - Pharmaceutical Technology

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney disease.

Read Full Article
European Medical JournalEuropean Medical Journal

AstraZeneca pays $160m for FibroGen's China subsidary

FibroGen, Inc. has announced the sale of its Chinese subsidiary to AstraZeneca, including the rights to roxadustat in China.

Read Full Article
Endpoints NewsEndpoints News

AstraZeneca buys FibroGen’s China unit for local control of anemia drug

AstraZeneca is furthering its presence in China by gaining complete control of FibroGen's subsidiary in the country for about $160 million. The Thursday morning move gives the UK pharma giant a ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Endpoints News broke the news in on Thursday, February 20, 2025.
Sources are mostly out of (0)

Similar News Topics

China

China

News
For You
Search
BlindspotLocal